Methyldopa-induced hemolytic anemia in a 15 year old presenting as near-syncope

J. S. Naidorf, J. M. Kennedy, John W. Becher

Research output: Contribution to journalArticlepeer-review

Abstract

Methyldopa is an antihypertensive medication which is available generically and under the trade name Aldomet® that is widely prescribed in the adult population and infrequently used in children. Methyldopa causes an autoimmune hemolytic anemia in a small percentage of patients who take the drug. We report a case of methyldopa-induced hemolytic anemia in a 15-year-old boy who presented to the emergency department with near-syncope. The boy had been treated with intravenous methyldopa during a trauma admission seven weeks prior to presentation. Evaluation revealed a hemoglobin of three grams, 3+ Coombs' test with polyspecific anti-human globulin and monospecific IgG reagents, and a warm reacting autoantibody. Transfusion and corticosteroid therapy resulted in a complete recovery of the patient. Emergency physicians treating children must be aware of this syndrome in order to diagnose and treat it correctly. A brief review of autoimmune and drug-induced hemolytic anemias is provided.

Original languageAmerican English
JournalPediatric Emergency Care
Volume6
StatePublished - Jan 1 1990

Keywords

  • Anemia
  • Diagnosis
  • Differential
  • Emergencies
  • Hemolytic
  • adolescent
  • adverse drug reaction
  • article
  • autoimmunity
  • case report
  • cotrimoxazole
  • drug therapy
  • emergency treatment
  • hemolytic anemia
  • human
  • male
  • methyldopa
  • phenytoin
  • prednisone
  • syncope

Disciplines

  • Emergency Medicine

Cite this